Vitamin K: The coagulation vitamin that became omnipotent, Thrombosis and Haemostasis, vol.98, pp.120-125, 2007. ,
DOI : 10.1160/TH07-04-0266
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein, Nature, vol.386, issue.6620, pp.78-81, 1997. ,
DOI : 10.1038/386078a0
Polymorphisms of the Human Matrix Gla Protein (MGP) Gene, Vascular Calcification, and Myocardial Infarction, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.11, pp.2386-2393, 2000. ,
DOI : 10.1161/01.ATV.20.11.2386
Vitamin K Epoxide Reductase: A Protein Involved in Angiogenesis, Molecular Cancer Research, vol.3, issue.6, pp.317-323, 2005. ,
DOI : 10.1158/1541-7786.MCR-04-0221
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, vol.427, issue.6974, pp.537-541, 2004. ,
DOI : 10.1038/nature02214
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance, Journal of Thrombosis and Haemostasis, vol.27, issue.7, pp.1533-1535, 2005. ,
DOI : 10.1038/nature02214
Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-2293, 2005. ,
DOI : 10.1056/NEJMoa044503
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation, Thromb Haemost, vol.94, pp.773-779, 2005. ,
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, vol.106, issue.1, pp.135-140, 2005. ,
DOI : 10.1182/blood-2005-01-0341
Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles, Thrombosis and Haemostasis, vol.98, pp.570-578, 2007. ,
DOI : 10.1160/TH07-07-0454
Antivitamines K et??pharmacog??n??tique: vers une??meilleure compr??hension de??la??variabilit?? individuelle de??l'effet dose???r??ponse, Pathologie Biologie, vol.55, issue.6, pp.295-298, 2007. ,
DOI : 10.1016/j.patbio.2007.04.001
La vitamine K ??poxyde r??ductase: du??sang neuf??dans??les??traitements anticoagulants oraux, La Revue de M??decine Interne, vol.27, issue.12, pp.979-982, 2006. ,
DOI : 10.1016/j.revmed.2006.09.004
VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection), Circulation, vol.113, issue.12, pp.1615-1621, 2006. ,
DOI : 10.1161/CIRCULATIONAHA.105.580167
Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study, Journal of Thrombosis and Haemostasis, vol.128, issue.10, pp.2020-2024, 2007. ,
DOI : 10.1532/IJH97.06082
URL : https://hal.archives-ouvertes.fr/hal-00688300
Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans, Thrombosis and Haemostasis, vol.97, pp.998-1002, 2007. ,
DOI : 10.1160/TH06-11-0643
Common VKORC1 variants are not associated with arterial or venous thrombosis, Journal of Thrombosis and Haemostasis, vol.5, issue.10, pp.2025-2027, 2007. ,
DOI : 10.1038/sj.clpt.6100144
The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study, Journal of Thrombosis and Haemostasis, vol.90, issue.8, pp.1334-1340, 2004. ,
DOI : 10.1046/j.1538-7836.2003.00008.x
P2Y12 H2 Haplotype Is Associated With Peripheral Arterial Disease: A Case-Control Study, Circulation, vol.108, issue.24, pp.2971-2973, 2003. ,
DOI : 10.1161/01.CIR.0000106904.80795.35